A recent study holds promise for the development of a new type of drug to alleviate immune deficiency caused by cancer treatment, radiation injury, or certain diseases.

March is Kidney Cancer Awareness Month. Watch the latest videos of our kidney cancer experts discussing advances in diagnosis and personalized treatment at our CancerSmart lecture series.

Beginning in April 2013, physician-scientist Charles Sawyers will serve as President of the American Association for Cancer Research, the world’s oldest and largest professional organization dedicated to advancing cancer research.

Researchers have identified a set of genetic abnormalities that can enhance prognostic accuracy and aid treatment selection for people with acute myelogenous leukemia (AML).

Findings from a multidisciplinary research team led by Memorial Sloan-Kettering medical oncologist and immunologist Jedd Wolchok could help shed light on the immune system’s role in fighting cancer.

Two Memorial Sloan-Kettering studies provide new clues about genetic mutations that affect cell behavior and play a role in several types of cancer.

The recent FDA approval of axitinib provides a viable treatment option for patients who progress on or cannot tolerate the side effects of other approved drugs for the disease.